Hypermarcas (OTCMKTS:HYPMY) Raised to “Hold” at Zacks Research

Hypermarcas (OTCMKTS:HYPMY) was upgraded by research analysts at Zacks Research to a “hold” rating in a report issued on Wednesday,Zacks.com reports.

Hypermarcas Stock Performance

OTCMKTS HYPMY opened at $4.69 on Wednesday. Hypermarcas has a 52-week low of $3.71 and a 52-week high of $5.50. The company has a 50-day simple moving average of $4.42 and a 200 day simple moving average of $4.47. The company has a debt-to-equity ratio of 0.61, a quick ratio of 0.84 and a current ratio of 1.27. The company has a market capitalization of $3.30 billion, a PE ratio of 9.77 and a beta of 0.75.

Hypermarcas (OTCMKTS:HYPMY) last posted its quarterly earnings data on Wednesday, April 29th. The company reported $0.10 earnings per share (EPS) for the quarter. Hypermarcas had a net margin of 19.41% and a return on equity of 14.08%. The business had revenue of $383.13 million during the quarter. On average, research analysts predict that Hypermarcas will post 0.53 EPS for the current year.

About Hypermarcas

Hypermarcas SA is a Brazil-based consumer health and pharmaceutical company whose shares trade over the counter in the United States under the symbol HYPMY. Founded in the early 2000s and headquartered in Rio de Janeiro, the company operates as a holding group for a broad portfolio of branded products in the healthcare and personal care sectors.

Through its various subsidiaries, Hypermarcas develops, manufactures and markets prescription and over-the-counter medications, alongside personal care, baby care, home care and nutritional supplement products.